share_log

Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews

Benzinga ·  May 2 22:00

In the preceding three months, 15 analysts have released ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ), presenting a wide array of perspectives from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings68100
Last 30D10000
1M Ago01000
2M Ago43000
3M Ago14100

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $195.73, a high estimate of $230.00, and a low estimate of $131.00. Marking an increase of 1.35%, the current average surpasses the previous average price target of $193.12.

price target chart

Analyzing Analyst Ratings: A Detailed Breakdown

A clear picture of Jazz...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment